Multiple Myeloma in Relapse Recruiting Phase 2 Trials for Pomalidomide (DB08910)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03030261Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaTreatment
NCT03601624Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in MexicansTreatment